Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. RosenbergGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: [email protected]Jean Hoffman‐CensitsKimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USATom PowlesBarts Cancer Institute ECMC, Barts Health and the Royal Free NHS Trust, Queen Mary University of London, London, UKMichiel S. van der HeijdenDepartment of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, NetherlandsArjun Vasant BalarGenitourinary Cancers Program, Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY, USAAndrea NecchiDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ItalyNancy A. DawsonMedstar Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USAPeter H. O’DonnellSection of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USAAni Sarkis BalmanoukianThe Angeles Clinic and Research Institute, Los Angeles, CA, USAYohann LoriotDepartment of Cancer Medicine, Gustave-Roussy Cancer Campus, Villejuif, University of Paris Sud, Paris, FranceSandy SrinivasDivision of Oncology/Department of Medicine, Stanford University School of Medicine, Stanford, CA, USAMargitta RetzDepartment of Urology, Klinikum rechts der Isar, Technische Universität München, Munich, GermanyPetros GrivasDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USARichard W. JosephDepartment of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USAMatthew D. GalskyDivision of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USAMark T. FlemingVirginia Oncology Associates, US Oncology Research, Norfolk, VA, USADaniel P. PetrylakSmilow Cancer Center, Yale University, New Haven, CT, USAJosé Luis Perez‐GraciaDepartment of Oncology, Clínica Universidad de Navarra, University of Navarra, Pamplona, Navarre, SpainHoward A. BurrisSarah Cannon Research Institute, Nashville, TN, USA; Tennessee Oncology, Nashville, TN, USADaniel CastellanoMedical Oncology Department, Genitourinary Oncology Unit, University Hospital 12 de Octubre, Madrid, SpainChristina CanilDivision of Medical Oncology, Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, The Ottawa Hospital Cancer Centre, Ottawa, ON, CanadaJoaquim BellmuntLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USADean F. BajorinGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USADorothee NicklesRichard BourgonGarrett M. FramptonFoundation Medicine Inc, Cambridge, MA, USANa CuiSanjeev MariathasanOyewale O. AbidoyeGregg FineRobert DreicerDivision of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA
2016en
ABI
Annotatsiya
Annotatsiya mavjud emas.
Identifikatorlar
Iqtiboslar va manbalar
3 ta iqtibos0 ta foydalanilgan manba